Qiagen N.V. (QGEN)

Market Cap	9.63B
Revenue (ttm)	2.07B
Net Income (ttm)	405.37M
Shares Out	216.84M
EPS (ttm)	1.84
PE Ratio	24.16
Forward PE	18.04
Dividend	$1.51 (3.40%)
Ex-Dividend Date	Jul 2, 2025

Volume	1,279,734
Open	44.66
Previous Close	44.35
Day's Range	43.91 - 44.74
52-Week Range	37.63 - 51.88
Beta	0.68
Analysts	Buy
Price Target	50.68 (+14.07%)
Earnings Date	Nov 4, 2025

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Analyst Summary

According to 7 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $50.68, which is an increase of 14.07% from the latest price.

Price Target

$50.68

(14.07% upside)

Analyst Consensus: Buy